Christopher M. Kramer

Active 1994–2025

153
Papers
30,575
Citations
88
h-index
144
i10-index

Citations

Citations per year for Christopher M. Kramer1995: 4 citations1996: 3 citations1997: 5 citations1998: 14 citations1999: 25 citations2000: 24 citations2001: 20 citations2002: 19 citations2003: 36 citations2004: 46 citations2005: 34 citations2006: 32 citations2007: 72 citations2008: 81 citations2009: 97 citations2010: 105 citations2011: 139 citations2012: 134 citations2013: 162 citations2014: 157 citations2015: 136 citations2016: 172 citations2017: 173 citations2018: 176 citations2019: 565 citations2020: 783 citations2021: 1,038 citations2022: 842 citations2023: 713 citations2024: 1,344 citations2025: 907 citations2026: 47 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,936 citing papers, 23.6% of this breakdownUnited Kingdom: 1,294 citing papers, 10.4% of this breakdownItaly: 894 citing papers, 7.2% of this breakdownGermany: 878 citing papers, 7.1% of this breakdownChina: 681 citing papers, 5.5% of this breakdownNetherlands: 557 citing papers, 4.5% of this breakdownCanada: 531 citing papers, 4.3% of this breakdownFrance: 374 citing papers, 3% of this breakdownSpain: 340 citing papers, 2.7% of this breakdownAustralia: 307 citing papers, 2.5% of this breakdownSwitzerland: 295 citing papers, 2.4% of this breakdownJapan: 246 citing papers, 2% of this breakdown
0%23.6%Other 24.8%

Fields

  • Medicine87.4%
  • Biochemistry, Genetics and Molecular Biology4.8%
  • Engineering2.2%
  • Neuroscience1.3%
  • Computer Science1.2%
  • Immunology and Microbiology0.9%
  • Other2.2%

Topics

  • Cardiac Imaging and Diagnostics11.6%
  • Cardiovascular Function and Risk Factors8.4%
  • Cardiomyopathy and Myosin Studies5.1%
  • Advanced MRI Techniques and Applications4.8%
  • Viral Infections and Immunology Research2.8%
  • Cardiovascular Effects of Exercise2.7%
  • Other64.6%

Coauthors

All papers

Open in search
  1. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gilbert R. Upchurch, Aaron W. Aday, Ali Azizzadeh, Michael L. Boisen, Beau Hawkins, Christopher M. Kramer, Jessica G.Y. Luc, Thomas E. MacGillivray, S. Chris Malaisrie, Kathryn Osteen, Himanshu J. Patel, Parag J. Patel, Wanda M. Popescu, Evelio Rodríguez, Rebecca Sorber, Philip S. Tsao, Annabelle Santos Volgman - Circulation 2022 cited by 1,841

  2. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 783

  3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emeline M. Van Craenenbroeck, Miloš Kubánek, David Zemánek, Morten K. Jensen, Jens Mogensen, Jens Jakob Thune, Philippe Charron, Albert Hagège, Olivier Lairez, Jean‐Noël Trochu, Christoph Axthelm, H DUENGEN, Norbert Frey, Veselin Mitrović, Michael R. Preusch, Jeanette Schulz‐Menger, Tim Seidler, Michael Arad, Majdi Halabi, Amos Katz, Daniel Monakier, Offir Paz, Samuel Viskin, Donna R. Zwas, Iacopo Olivotto, Hans‐Peter Brunner‐La Rocca, Michelle Michels, Dariusz Dudek, Zofia Oko‐Sarnowska, Artur Oręziak, Wojciech Wojakowski, Nuno Cardim, Helder Pereira, Roberto Barriales‐Villa, Pablo García Pavía, Juan Gimeno Blanes, Rafael Hidalgo Urbano, Luis Miguel Rincón Diaz, Perry Elliott, Zaheer Yousef, Theodore P. Abraham, Kia Afshar, Paulino Álvarez, Richard G. Bach, Richard C. Becker, Lubna Choudhury, David Fermin, Daniel Jacoby, John L. Jefferies, Christopher M. Kramer, Neal K. Lakdawala, Steven J. Lester, Ali J. Marian, Ahmad Masri, Matthew J. Maurer, Sherif F. Nagueh, Anjali Owens, David S. Owens, Florian Rader, Sara Saberi, Mark V. Sherrid, Jamshid Shirani, John D. Symanski, Aslan T. Turer, Andrew Wang, Omar Wever‐Pinzon, Matthew T. Wheeler, Timothy C. Wong, Mohamad H. Yamani - The Lancet 2020 cited by 1,210

  4. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation

    Authors: , , , , , , , , , , - Journal of the American College of Cardiology 2018 cited by 1,970

  5. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update

    Authors: , , , , , - Journal of Cardiovascular Magnetic Resonance 2020 cited by 1,197

  6. Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update

    Authors: , , , , , , , , , , , - Journal of Cardiovascular Magnetic Resonance 2020 cited by 972

  7. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing

    Authors: , , , , , , , , , , , - Journal of Cardiovascular Magnetic Resonance 2013 cited by 1,515

  8. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 193

  9. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lubna Choudhury, Andrew Crean, Dana Dawson, Milind Y. Desai, Eleanor Elstein, Andrew Flett, Matthias G. Friedrich, Stephen B. Heitner, Adam Helms, Daniel Jacoby, Han Kim, Bette Kim, Éric Larose, Masliza Mahmod, Heiko Mahrholdt, Martin S. Maron, Gerry P McCann, Michelle Michels, Saidi Mohiddin, Sherif F. Nagueh, David E. Newby, Iacopo Olivotto, Anjali Owens, François Pierre-Mongeon, Sanjay Prasad, Ornella Rimoldi, Michael Salerno, Jeanette Schulz‐Menger, Mark V. Sherrid, Peter Swoboda, Albert C. van Rossum, Jonathan W. Weinsaft, James A. White, Eric E. Williamson, Rafik Tadros, James S. Ware, Connie R. Bezzina, Martin Farrall, Hugh Watkins - Nature Genetics 2021 cited by 339

  10. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William Bradlow, Michael Salerno, Stephen B. Heitner, Sanjay Prasad, Saidi Mohiddin, Peter Swoboda, Heiko Mahrholdt, Chiara Bucciarelli‐Ducci, Jonathan W. Weinsaft, Han Kim, Gerry P McCann, Albert C. van Rossum, Eric E. Williamson, Andrew Flett, Dana Dawson, François‐Pierre Mongeon, Iacopo Olivotto, Andrew Crean, Anjali Owens, Lisa Anderson, Elena Biagini, David E. Newby, Colin Berry, Bette Kim, Éric Larose, Theodore P. Abraham, Mark V. Sherrid, Sherif F. Nagueh, Ornella Rimoldi, Eleanor Elstein, Camillo Autore - Journal of the American College of Cardiology 2019 cited by 321

  11. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 235

  12. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

    Authors: , , , , , , , , , , - Journal of the American College of Cardiology 2024 cited by 142

  13. Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2019 cited by 351

  14. Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology

    Authors: , , , , , , , , , , , , , , - American Journal of Preventive Cardiology 2022 cited by 99

  15. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 114

  16. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

    Authors: , , , , , , , , , - Nature Medicine 2024 cited by 118

  17. Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2021 cited by 124

  18. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging

    Authors: , , , , , - Journal of the American College of Cardiology 2021 cited by 133

  19. Late Gadolinium Enhancement on Cardiac Magnetic Resonance Predicts Adverse Cardiovascular Outcomes in Nonischemic Cardiomyopathy

    Authors: , , , , , - Circulation Cardiovascular Imaging 2013 cited by 377

  20. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy

    Authors: , - JACC. Cardiovascular imaging 2017 cited by 309

  21. Criteria for Evaluation of Novel Markers of Cardiovascular Risk

    Authors: , , , , , , , , , , , , , , , , , - Circulation 2009 cited by 1,133

  22. Coronary Microvascular Dysfunction, Microvascular Angina, and Treatment Strategies

    Authors: , , , , , - JACC. Cardiovascular imaging 2015 cited by 301

  23. Functional and Economic Impact of INOCA and Influence of Coronary Microvascular Dysfunction

    Authors: , , , , , , , , , - JACC. Cardiovascular imaging 2021 cited by 101

  24. Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations

    Authors: , , , , , , , , , , , , , , , , , - Journal of Cardiovascular Magnetic Resonance 2022 cited by 86